#hepatitis c drug market forecast

[colinwilson11]

Treatment Of Liver Cirrhosis Market To Grow At Highest Pace Due To Rising Alcohol Intake

Liver cirrhosis refers to scarring (fibrosis) of the liver tissue and poor functioning of the liver. It is caused by excessive alcohol consumption over many years or due to chronic hepatitis virus infections such as hepatitis B or C. The progression of fibrosis leads to nodule formation and ultimately to cirrhosis. The key symptoms of liver cirrhosis include jaundice, fatigue, abdominal pain, weakness, loss of appetite, nausea and vomiting. Treatment for liver cirrhosis depends on the severity of the disease and includes medications to improve liver functions, antibiotics to treat infections, diuretics to remove excess fluid and sometimes orthotopic liver transplantation.

The Liver Cirrhosis Market is estimated to be valued at US$ 1.41 Bn in 2024 and is expected to exhibit a CAGR of 5.2% over the forecast period 2024-2031.

Key Takeaways

Key players operating in the liver cirrhosis market are Madrigal Pharmaceuticals, Inc., Galectin Therapeutics Inc., Grifols Therapeutics LLC, Cyma Bay Therapeutics, Akero Therapeutics, Inc.

Key players operating in the liver cirrhosis market are increasingly investing in R&D to develop advanced treatment options. For instance, Madrigal Pharmaceuticals is developing resmetirom, a first-in-class thyroid hormone receptor beta-selective agonist for the treatment of non-alcoholic steatohepatitis (NASH) and liver cirrhosis.

The growing prevalence of excessive alcohol consumption and obesity are major factors fueling the demand for liver cirrhosis treatment solutions. According to WHO, around 3 million deaths each year result from harmful use of alcohol. Excessive alcohol intake damages liver cells making the organ less able to regenerate, leading to the development of cirrhosis over the years.

Technological advancements in liver transplantation techniques coupled with the emergence of effective post-transplant medications have increased the eligibility of patients and survival rates post transplantation. Shortage of liver donors however remains a key challenge. Companies are investing in development of artificial or bio-engineered livers as potential alternatives.

Market Trends

Increasing Adoption Of Targeted Therapies: Pharma companies are focusing on developing targeted therapies for liver cirrhosis that specifically act on certain molecular targets or pathways involved in disease progression. For example, Galectin Therapeutics' drug belapectin blocks galectin-3 activity involved in fibrotic response and necrosis.

Rise Of Combination Therapies: Due to multifactorial nature of the disease, companies are exploring efficacy of combining two or more treatment modalities for synergistic effects. For example, combination of antiviral medications with immunomodulators to achieve sustained virologic response.

Market Opportunities

Asia Pacific presents high growth prospects owing to changing lifestyles, abusive consumption of alcohol and growing obesity rates. Public-private partnerships can help facilitate more affordable healthcare access in emerging economies.

Emergence of non-invasive diagnostic tools leveraging imaging and biomarkers hold potential to precisely diagnose and monitor disease progression and treatment response without need for repeated liver biopsies. This can increase patient acceptance and compliance.

Impact Of COVID-19 On Liver Cirrhosis Market Growth

The COVID-19 pandemic has significantly impacted the growth of the liver cirrhosis market. During the initial phases of the pandemic, factors like lockdowns, restrictions on non-essential medical services led to postponement of diagnosis procedures and delay in treatment. This adversely impacted the market growth initially. However, as the healthcare sector learned to cope and adapt to the new normal, telehealth services gained prominence helping maintain continuity of care virtually. With the development and availability of vaccines as well, the market is recovering fast. However, challenges like availability of medical staff, hospital beds, and potential risks of severe COVID infection in cirrhosis patients still persist and need to be addressed. The immediate focus post pandemic is to boost diagnosis and treatment rates back to pre-COVID levels. Intensifying awareness campaigns and policies promoting community healthcare can aid in early detection and management of cirrhosis cases.

Geographical Regions With Highest Liver Cirrhosis Market Value

North America dominates the Liver Cirrhosis Market in terms of value. The region accounted for over 35% market share in 2024 owing to rising prevalence of cirrhosis caused by non-alcoholic steatohepatitis (NASH) and alcohol abuse. Growing healthcare spending and availability of advanced treatment options have further augmented the regional market. Europe ranks second with major markets being Germany, United Kingdom, France and Italy. Developed healthcare infrastructure, supportive reimbursement environment and presence of key industry players have boosted the European market.

Fastest Growing Region For Liver Cirrhosis Market

Asia Pacific is identified as the fastest growing regional market for liver cirrhosis expected to expand at a CAGR of around 7% during the forecast years. Growing consumption of alcohol, rising obesity rates attributed to changing lifestyles and dietary habits have majorly contributed to increased cirrhosis burden in the region. Countries like China, India and Japan have emerged as high potential markets. Rapid economic development, rising healthcare expenditure, growing medical tourism are some factors favoring the Asia Pacific liver cirrhosis market. Initiatives to spread awareness about lifestyle-related liver diseases can further augment the regional market opportunities.

Get more insights on this topic: https://www.trendingwebwire.com/liver-cirrhosis-market-poised-for-growth-amid-rising-adoption-of-targeted-therapies/

Author Bio:

Alice Mutum is a seasoned senior content editor at Coherent Market Insights, leveraging extensive expertise gained from her previous role as a content writer. With seven years in content development, Alice masterfully employs SEO best practices and cutting-edge digital marketing strategies to craft high-ranking, impactful content. As an editor, she meticulously ensures flawless grammar and punctuation, precise data accuracy, and perfect alignment with audience needs in every research report. Alice's dedication to excellence and her strategic approach to content make her an invaluable asset in the world of market insights. (LinkedIn: www.linkedin.com/in/alice-mutum-3b247b137 )

What Are The Key Data Covered In This Liver Cirrhosis Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the Liver Cirrhosis Market's growth between 2024 and 2031.

:- Accurate calculation of the size of the Liver Cirrhosis Market and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- Liver Cirrhosis Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of Liver Cirrhosis Market vendors

FAQ’s

Q.1 What are the main factors influencing the Liver Cirrhosis Market?

Q.2 Which companies are the major sources in this industry?

Q.3 What are the market’s opportunities, risks, and general structure?

Q.4 Which of the top Liver Cirrhosis Market companies compare in terms of sales, revenue, and prices?

Q.5 Which businesses serve as the Liver Cirrhosis Market’s distributors, traders, and dealers?

Q.6 How are market types and applications and deals, revenue, and value explored?

Q.7 What does a business area’s assessment of agreements, income, and value implicate?

*Note: 1. Source: Coherent Market Insights, Public sources, Desk research 2. We have leveraged AI tools to mine information and compile it

[credenceresearchdotblog]

The antiviral drugs market is projected to grow from USD 65,107 million in 2024 to USD 108,519 million by 2032, reflecting a compound annual growth rate (CAGR) of 6.70%.The global antiviral drugs market is a crucial segment of the pharmaceutical industry, dedicated to the development, production, and distribution of medications that treat viral infections. These drugs are designed to inhibit the replication of viruses, thereby reducing the severity and duration of infections. The market for antiviral drugs has gained significant attention, especially in light of recent global health crises such as the COVID-19 pandemic. This article provides an overview of the antiviral drugs market, highlighting its current trends, growth drivers, challenges, and future prospects.

Browse the full report at https://www.credenceresearch.com/report/antiviral-drugs-market

Market Overview

The antiviral drugs market is characterized by a wide range of products targeting various viral infections, including HIV, hepatitis, herpes, influenza, and coronaviruses. The market has witnessed substantial growth over the past decade, driven by advancements in biotechnology, increasing prevalence of viral infections, and the urgent need for effective treatments.

As of 2024, the global antiviral drugs market is valued at approximately $40 billion and is projected to grow at a compound annual growth rate (CAGR) of around 6% over the next five years. The market's growth is primarily fueled by the rising incidence of chronic viral infections, the aging population, and the ongoing research and development (R&D) efforts in the pharmaceutical industry.

Key Market Drivers

1. Increasing Prevalence of Viral Infections: The rising incidence of viral infections, particularly HIV, hepatitis B and C, and influenza, is one of the primary drivers of the antiviral drugs market. For instance, the World Health Organization (WHO) estimates that approximately 38 million people worldwide are living with HIV, necessitating continuous demand for antiviral therapies.

2. Technological Advancements: The advent of novel drug delivery systems, such as long-acting injectables and nanotechnology-based formulations, has revolutionized the treatment landscape. These advancements have improved drug efficacy, reduced side effects, and enhanced patient compliance, thereby boosting market growth.

3. Government Initiatives and Funding: Governments and international organizations are increasingly investing in the development and distribution of antiviral drugs. Initiatives such as the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund to Fight AIDS, Tuberculosis, and Malaria have significantly contributed to the accessibility of antiviral medications in low- and middle-income countries.

Challenges and Restraints

Despite the positive growth trajectory, the antiviral drugs market faces several challenges:

1. High Cost of R&D: The development of antiviral drugs is a complex and costly process, often requiring years of research, clinical trials, and regulatory approvals. The high cost of R&D, coupled with the risk of failure, poses a significant challenge to market players.

2. Drug Resistance: The emergence of drug-resistant viral strains is a growing concern in the antiviral drugs market. For example, resistance to antiretroviral drugs used in HIV treatment has been reported, leading to reduced drug efficacy and the need for new therapeutic approaches.

3. Stringent Regulatory Requirements: The approval process for antiviral drugs is highly regulated, with stringent safety and efficacy standards. Navigating these regulatory requirements can be time-consuming and costly, potentially delaying the launch of new drugs.

4. Limited Access in Low-Income Regions: While antiviral drugs have become more accessible in many parts of the world, there are still significant disparities in access, particularly in low-income regions. The high cost of treatment and inadequate healthcare infrastructure continue to hinder the widespread adoption of antiviral therapies in these areas.

Future Outlook

The future of the antiviral drugs market looks promising, with continued advancements in drug development and a growing focus on precision medicine. The integration of artificial intelligence (AI) and machine learning in drug discovery is expected to accelerate the development of new antiviral therapies, offering more targeted and effective treatments.

Moreover, the market is likely to witness increased collaboration between pharmaceutical companies, academic institutions, and government agencies, fostering innovation and expanding the availability of antiviral drugs worldwide. The ongoing efforts to combat emerging viral threats, such as new strains of influenza and coronaviruses, will further drive the demand for antiviral therapies.

Key Player Analysis

Roche

Gilead

GlaxoSmithKline

Bristol-Myers-Squibb

Abbott

AstraZeneca

Cipla

Bayer AG

Johnson & Johnson

Merck & Co

Segments:

Based on Product type:

Hepatitis-C antivirals

HIV antivirals

Herpes antivirals

Hepatitis-B antivirals

Influenza antivirals

Others (Pneumonia, Flu, etc.)

Based on End User:

Hospitals

Clinics

Ambulatory Surgical Centers

Based on the Geography:

North America

US

Canada

Mexico

Europe

Germany

France

UK.

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

South-east Asia

Rest of Asia Pacific

Latin America

Brazil

Argentina

Rest of Latin America

Middle East & Africa

GCC Countries

South Africa

Rest of the Middle East and Africa

Browse the full report at https://www.credenceresearch.com/report/antiviral-drugs-market

About Us:

Credence Research is committed to employee well-being and productivity. Following the COVID-19 pandemic, we have implemented a permanent work-from-home policy for all employees.

Contact:

Credence Research

Please contact us at +91 6232 49 3207

Email: sales@credenceresearch.com

Website: www.credenceresearch.com

[omkarpatel]

The Cholangiocarcinoma Market is Estimated to Witness High Growth Owing to the Rising Incidence of Bile Duct Cancer

Cholangiocarcinoma, also known as bile duct cancer, is a relatively rare type of cancer that forms in the bile duct. It develops in the bile ducts (the tubes that carry bile from the liver to the small intestine) or in the gallbladder. The key products associated with the cholangiocarcinoma market include biomarkers, imaging, biopsy, surgery, chemotherapy, and radiation therapy. These products aid in the early detection, staging, and effective treatment of bile duct cancer. The global Cholangiocarcinoma Market is estimated to be valued at US$ 7,275.7 Mn in 2023 and is expected to exhibit a CAGR of 7.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Opportunity: The rising incidence of bile duct cancer represents a major market opportunity. According to the global cancer statistics 2020 reports, the age-standardized rates (ASRs) for cholangiocarcinoma have increased globally by approximately 2% per year over the past 20 years. The aging worldwide population and exposures to various risk factors like primary sclerosing cholangitis, hepatitis B and C infection, liver flukes, obesity etc. have contributed to the rise in bile duct cancer incidence rates. With limited treatment options available, this increase in patient pool suffering from cholangiocarcinoma presents a worthwhile opportunity for players in the market to introduce safer and more effective diagnostic measures as well as therapeutic drugs and devices. Porter's Analysis Threat of new entrants: The high research and development costs associated with bringing new oncology drugs to market pose a significant barrier to entry.

Bargaining power of buyers: Individual patients have little negotiating power, though insurance companies and government payers have some leverage over pricing.

Bargaining power of suppliers: Suppliers of specialized oncology drugs have some power given the lack of substitutes and life-saving nature of their products.

Threat of new substitutes: No close substitutes currently exist for approved targeted therapies and immunotherapies for cholangiocarcinoma treatment.

Competitive rivalry: Competition is high amongst major pharmaceutical companies to develop and commercialize new targeted therapies and immunotherapies for cholangiocarcinoma patients. SWOT Analysis Strengths: Advancements in precision medicine and targeted therapies offer potential for better outcomes. Growing clinical trial activity is expanding treatment options. Weaknesses: Low disease awareness and rarity of cholangiocarcinoma present challenges for research funding and drug development. Late stage at diagnosis often limits curative treatment potential. Opportunities: Further elucidating the molecular underpinnings of cholangiocarcinoma may lead to additional targets. Combination therapy regimens could boost efficacy over single agents. Threats: High cost of novel oncology drugs may limit accessibility or insurance coverage for certain patients. Safety and tolerability issues may cause some therapies to have only narrow uses. Key Takeaways The global cholangiocarcinoma market is expected to witness high growth over the forecast period of 2023 to 2030. The global Cholangiocarcinoma Market is estimated to be valued at US$ 7,275.7 Mn in 2023 and is expected to exhibit a CAGR of 7.6% over the forecast period 2023 to 2030. Faster growth will be seen in Asia due to rising disease incidence associated with liver fluke infections in China, Southeast Asia, and India. The US market currently dominates due to large healthcare budgets and high adoption rates for premium-priced cancer therapies. Asia Pacific due to escalating cholangiocarcinoma cases linked to liver fluke infections which remain endemic in Thailand, China, Vietnam and other developing countries in the region. North America is expected to maintain its leading revenue share over the analysis period owing to well-established healthcare systems and rapid uptake of new oncology treatments in the US. Key players operating in the Cholangiocarcinoma market are Johnson & Johnson Services, Inc., Cooper Companies Inc., Lifecell Corporation (Allergan Plc), W. L. Gore & Associates, Inc., Maquet Holding B.V. & Co. KG, Becton, Dickinson and Company, Medtronic Plc, Cook Medical Inc., Baxter International Inc., and B. Braun Melsungen AG.

[abcergh]

Global Smart Syringes Market Size, Share, Growth Analysis, By Product(Auto-disable syringes, Active safety syringes), By Application(Drug delivery, Vaccination), By Age Group(Pediatrics and Adults), By End User(Hospitals and HMOs, Diabetic Patients)

Global Smart Syringes Market Insights

Global Smart Syringes Market size was valued at USD 7.84 billion in 2021 and is poised to grow from USD 8.45 billion in 2022 to USD 15.41 billion by 2030, growing at a CAGR of 7.8% in the forecast period (2023-2030).

Syringes are medical devices used to inject fluid or withdraw fluid from the body. A medical syringe consists of a needle attached to a hollow cylinder fitted with a sliding piston. The World Health Organization observes unsafe syringe use around the world, leading to widespread infection among health workers and patients. Unsafe syringe use can cause abscesses, septicaemia, and nerve damage, and also in severe cases, haemorrhagic fevers and malaria are transmitted. Smart syringes are equipped with features that prevent needle stick injuries to the person using these syringes and prevent the transmission of blood-borne diseases such as hepatitis C virus, hepatitis B virus, and human immunodeficiency virus. They target numerous applications that include vaccination, drug delivery, and blood sampling.

Smart syringes perfectly address the need for safe injection practices by eliminating the reuse of syringes. So, the growing demand for minimally invasive procedures among the population is driving the demand for smart syringes. Smart syringes prevent needle stick injuries associated with traditional injections. Recommendations from the World Health Organization to adopt the use of smart syringes to prevent needle stick injuries and promote good injection practices worldwide are driving the growth of the global syringes market. The rising prevalence of blood-borne diseases due to unsafe injection practices has significantly boosted the growth of the global smart syringes market. The increasing incidence of chronic diseases and viral infections among the general population is one of the major reasons driving the global demand for smart syringes. It may also be due to an aging population that is more susceptible to serious medical problems. Additionally, increased demand for self-injecting drugs is driving market expansion.

Smart syringes are more expensive than conventional syringes, making global adoption difficult. Some are less expensive than single-use syringes. Others, depending on the technological advancement of the security systems, can cost up to five times more than others, making them expensive in some low- and middle-income nations, hampering the market growth.

Global Smart Syringes Market Segmental Analysis

Global smart syringes market is segmented on the basis of product, application, age group, end user, and region. On the basis of product, global smart syringes market is segmented into auto-disable syringes, active safety syringes, and passive safety syringes. On the basis of application, global smart syringes market is segmented into drug delivery, vaccination, and blood specimen collection. By age group, the Smart Syringes Market is segmented into Pediatrics and Adults. By End User, the Smart Syringes Market is segmented into Hospitals and HMOs, Diabetic Patients, Family Practices, Psychiatrics, and Others. On the basis of region, global smart syringes market is divided into North America, Europe, Asia Pacific and MEA.

Smart Syringes Market Analysis by Product

On the basis of product, global smart syringes market is segmented into auto-disable syringes, active safety syringes, and passive safety syringes. Auto-disable syringes segment has about 64% market share and is expected to grow at a significant CAGR during the forecast period.  Auto-disable syringes are the most popular type of smart syringe in hospitals and healthcare institutions, as they are single-use syringes that cannot be reused. Widespread use of self-sterilizing syringes in daily drug delivery to patients. The safety mechanism of this syringe prevents the spread of blood-borne infections, thus meeting the most important need for a smart syringe.

The passive safety syringe segment is expected to be the most competitive. The growth of this segment is expected to be driven by greater safety, the self-activation of safety features, and the convenience associated with the use of passive safety syringes. Growing awareness about the benefits of passive safety syringes among the diabetic community is expected to drive global demand.

Smart Syringes Market Analysis by Application

On the basis of application, global smart syringes market is segmented into drug delivery, vaccination, and blood specimen collection. The global smart syringe market is dominated by the drug delivery segment. The growing use of smart syringes as drug delivery devices in hospitals and clinics has increased the demand for smart syringes. The increasing number of various chronic diseases is increasing the use of smart syringes as a better tool for drug administration and higher drug absorption through injection, which is driving the growth of this segment.

The vaccination segment is expected to be the fastest-growing segment during the forecast period. The increasing global burden of infectious diseases coupled with continuous research and development operations of vaccine manufacturing companies is expected to drive the growth of this segment.

[alicesara611]

Safety Needles: A Vital Component of Healthcare Safety Measures - Market Insights By 2022 to 2028

The global safety needles market is expected to reach US$ 4.6 billion by 2028, growing at a CAGR of 9.9% during the forecast period. This growth is attributed to increasing awareness about the safety of healthcare workers and patients, growing prevalence of chronic diseases, and increasing demand for safety needles in developing countries.

Safety needles are medical devices that are designed to protect healthcare workers and patients from needle stick injuries. Needle stick injuries are accidental punctures of the skin with a contaminated needle, and they can transmit serious diseases such as HIV, hepatitis B, and hepatitis C. Safety needles are designed with a variety of features to prevent needle stick injuries, such as retractable needles, passive safety devices, and shielded needles.

Request A Sample Copy of This Research Report! https://bit.ly/49hV5Cz

Market Trends:

A number of trends are driving the growth of the safety needles market, including:

Increasing prevalence of blood-borne diseases: The prevalence of blood-borne diseases such as HIV, hepatitis B, and hepatitis C is increasing worldwide. This is driving the demand for safety needles to protect healthcare workers and patients from needle stick injuries.

Rising demand for injectable drugs and vaccines: The demand for injectable drugs and vaccines is increasing due to the growing prevalence of chronic diseases and the increasing number of vaccinations being administered. This is also driving the demand for safety needles.

Government initiatives to promote the use of safety needles: Governments around the world are implementing initiatives to promote the use of safety needles in healthcare settings. This is helping to raise awareness of the risks of needle stick injuries and the benefits of using safety needles.

Growing awareness of the risks of needle stick injuries: There is a growing awareness of the risks of needle stick injuries among healthcare workers and patients. This is driving the demand for safety needles.

Key Takeaways:

The global safety needles market is expected to reach US$ 4.6 billion by 2028, growing at a CAGR of 9.9% during the forecast period.

The increasing prevalence of chronic diseases, rising awareness of needlestick injuries, and government initiatives to promote the use of safety needles are driving the growth of the market.

Retractable safety syringes are the largest segment of the market, followed by non-retractable syringes.

Hospitals are the leading end-user segment, followed by clinics and ambulatory surgical centers.

North America is the largest regional market, followed by Europe and Asia Pacific.

Key Players:

BD

Terumo Medical Corporation

Becton, Dickinson and Company

Nipro Corporation

Cardinal Health

Medtronic

Novo Nordisk A/S

Eli Lilly and Company

Pfizer Inc.

AbbVie Inc.

Johnson & Johnson

Segmentation:

By Product:

Retractable safety syringes

Manual retractable safety syringes

Automatic retractable safety syringes

Non-retractable safety syringes

By End-use:

Hospitals

Clinics

Ambulatory surgical centers

Others

By Region:

North America

Europe

Asia Pacific

Latin America

Middle East and Africa

[ankit2396]

Hepatitis C Drug Market Segmentation, Research Methodology And Revenue Growth Forecast Till 2030

Global Hepatitis C Drug Market Size research report 2023 offers in-depth assessment of revenue growth, market definition, segmentation, industry potential, influential trends for understanding the future outlook and current prospects for the market.

Get a Sample Copy of the Report at – https://www.fortunebusinessinsights.com/industry-reports/hepatitis-c-drug-market-101562

The global hepatitis C drug market size was valued at USD 7.86 Billion in 2018 and is projected to reach USD 7.35 Billion by 2026, exhibiting a CAGR of -0.9% during the forecast period. 

Drivers & Restraints

The hepatitis C market is currently at a unique crossroad where the launch of new products such as the fixed-dose combination medications has led to the erosion of revenues of the competing companies. The newly launched medication by AbbVie called Mavyret has led to the drastic reduction of the revenue of the once market leader of the hepatitis C therapeutics market, Gilead. Mavyret has several advantages associated with it, such as the shorter treatment duration and is also significantly cheaper.

This study provides information about the sales and revenue during the historic and forecasted period of (2022 to 2028). Understanding the segments helps in identifying the importance of different factors that aid market growth. Estimations about the CAGR value for specific forecast period, market drivers, market restraints, and competitive strategies are assessed in this Hepatitis C Drug Market report.

This report focuses on Hepatitis C Drug Market volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Hepatitis C Drug Market market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East and Africa.

[meghanester]

Closed System Transfer Devices (CSTD) Market to Expand at a CAGR of ~15% | Driving Factors, Size, Revenue, Demand, and Opportunities During 2023-2035

Global Closed System Transfer Devices (CSTD) Market Key Insights

During the forecast period of 2023-2035, the global closed system transfer devices (CSTD) market is expected to reach an estimated value of ~USD 3500 million by 2035 by expanding at a CAGR of ~15%. The market further generated revenue of ~USD 800 million in the year 2022. Major key factors propelling the growth of the closed system transfer devices (CSTD) market are the higher utilization of closed system transfer devices to deliver antineoplastic drugs in the chemotherapy to treat the symptoms of cancer and the rising prevalence of cancer.

Market Definition of Closed System Transfer Devices (CSTD)

Closed system transfer devices (CSTD) is a system to reduce the risk of drug aerosols during the transfer of medication from one point to another. It also minimizes the risk of sharp exposure, and hazardous drug exposure and contamination. Closed-system transfer devices are used to eliminate the transfer of environmental contaminants. These devices generally come in a few design concepts that use sir-cleaning technology or physical barrier to prevent the mix of harmful drugs in the work environment.

Get a Sample PDF Brochure: https://www.researchnester.com/sample-request-4090

Global Closed System Transfer Devices (CSTD) Market: Growth Drivers

The growth of the global closed system transfer devices (CSTD) market can majorly be attributed to the rising prevalence of urinary tract infections and pneumonia to need the administration of antibiotics to cure the symptoms. Pneumonia is common in children and they cannot swallow antibiotics where the administration through CSTDs becomes necessary. For instance, the annual rate of death caused by pneumonia in America is estimated to be around 45000 while approximately 1 million adults suffer from it every year. On the other hand, a higher adoption rate of closed system transfer devices to avoid the side effects of chemo drugs such as, infertility, kidney and liver damage, and others are estimated to fuel the market growth during the forecast period. For instance, it was estimated that nearly 22% of acute renal infections are caused by medicinal drugs.

The global closed system transfer devices (CSTD) market is also estimated to grow majorly on account of the following:

Increasing number of chemotherapy boosting the demand for antineoplastic drugs

Rising prevalence of cancer

Growth in the adoption of closed-system transfer devices

Complexity in the oral administration of certain drugs

Technological advancement in the field of medicinal drugs

Request for customization @ https://www.researchnester.com/customized-reports-4090

Global Closed System Transfer Devices (CSTD) Market: Restraining Factor

There is a high possibility of drug leakage during the administration that can negatively impact the health of the healthcare provider. Hence this factor is expected to be the major hindrance for the growth of the global closed system transfer devices (CSTD) market during the forecast period.

Global Closed System Transfer Devices (CSTD) Market Segmentation 

By Type (Membrane-to-Membrane and Needleless)

The membrane-to-membrane segment, amongst all the other segments, is anticipated to garner the largest revenue by the end of 2035. The growth of the segment can be attributed to the fact that this type has the lowest rate of risk of contamination since it also comprises a double-membrane containment system. Drug contamination can cause many types of infections such as, hepatitis C, HIV, and others. It is estimated that approximately 1.4 million new infections of hepatitis C occur every year.

By Technology (Diaphragm, Compartmentalized, Filtration, Others)

By End-User (Hospitals & Clinics, Oncology Centers, and Others)

By Region

The Asia Pacific closed system transfer devices (CSTD) market is anticipated to hold the largest market share by the end of 2035 among the market in all the other regions. The surge in the cases of cancer in the region and growing awareness of the early diagnosis of this disease leading to the high requirement of chemotherapy is estimated to expand the market size over the forecast period. It was noted in 2018, nearly 5 million deaths were accounted to cancer while 8 million new cases of cancer were diagnosed in the same year.

Obtain this Report @ https://www.researchnester.com/reports/closed-system-transfer-devices-cstd-market/4090

The market research report on global closed system transfer devices (CSTD) also includes the market size, market revenue, Y-o-Y growth, and key player analysis applicable for the market in North America (U.S., and Canada), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific), Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC (Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), and Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa).

Key Market Players Featured in the Global Closed System Transfer Devices (CSTD) Market

Some of the key players of the global closed system transfer devices (CSTD) market are Becton, Dickinson and Company, B. Braun Melsungen AG, ICU Medical, Inc., Equashield, LLC, CODAN Medizinische Geräte GmbH & Co KG, Simplivia Healthcare Ltd., Corvida Medical, Inc., Caragen Ltd., Baxter International Inc., Pfizer Inc., and others.

About Research Nester

Research Nester, which is a leading service provider for strategic market research and consulting services, aims to provide unbiased, unparalleled market insights and industry analysis. These analyses help conglomerates, executives, and industries to take wise decisions for their businesses as well as for their future marketing strategy, expansion and investment among others. We believe that our expertise in the field of market research can help businesses to expand to its new horizon. Our team of research analysts can provide businesses a right guidance at the right time, while our out of box thinking helps our clients to take wise decision in order to avoid future uncertainties.

Contact for more Info:

AJ Daniel

Email: info@researchnester.com

U.S. Phone: +1 646 586 9123

U.K. Phone: +44 203 608 5919

[vanshika393]

Cirrhosis Market Share and Demand Analysis with Size, Growth Drivers and Forecast to 2030

The latest market report published by Credence Research, Inc. “Global Cirrhosis Market: Growth, Future Prospects, and Competitive Analysis, 2016 – 2028. The global cirrhosis market has witnessed rapid growth in recent years and is expected to grow at a CAGR of 4.2% between 2023 and 2030. The market was valued at USD 658.9 million in 2022 and is expected to reach USD 915.71 million in 2030.

Cirrhosis is a late stage of scarring (fibrosis) of the liver caused by many forms of liver diseases and conditions, such as hepatitis and chronic alcoholism. Over time, this scarring can progress to cirrhosis, which is characterized by the replacement of healthy liver tissue with scar tissue. Cirrhosis can lead to various complications and is a significant medical concern.

The "Cirrhosis Market" would encompass the various products and services related to the diagnosis, treatment, and management of cirrhosis. This market includes pharmaceutical drugs, medical devices, diagnostic tests, and healthcare services aimed at helping patients with cirrhosis manage their condition and improve their quality of life.

Here are some key dynamics that can impact the cirrhosis market:

Prevalence and Incidence Rates: The prevalence and incidence of cirrhosis can significantly affect the market. Factors such as the rising prevalence of chronic liver diseases (e.g., hepatitis C, non-alcoholic fatty liver disease) and alcohol-related liver damage contribute to the demand for cirrhosis-related treatments and healthcare services.

Medical Advancements: Advances in medical research and technology can lead to the development of new treatments, medications, and diagnostic tools for cirrhosis. Breakthroughs in liver transplantation techniques, drug therapies, and minimally invasive procedures can drive changes in treatment approaches and market dynamics.

Pharmaceutical Industry: Pharmaceutical companies play a crucial role in the cirrhosis market by developing and marketing drugs to manage cirrhosis-related complications. The introduction of novel medications to address liver fibrosis, hepatic encephalopathy, and portal hypertension can impact market growth.

Diagnostic Tools: Innovations in diagnostic methods, including non-invasive tests for liver fibrosis and cirrhosis (e.g., elastography), can influence early detection and monitoring of the disease. These advancements may lead to increased screening and diagnosis rates.

The following are some of the top market players and their market shares:

B. Braun Medical Inc

AstraZeneca

Histogen Inc

Stempeutics Research Pvt Ltd

Epic Research & Diagnostics Inc

Bayer AG

Sequana Medical AG

Browse 247 pages report Cirrhosis Market By Etiology (Alcoholic Cirrhosis Non-Alcoholic Fatty Liver Disease (NAFLD) Cirrhosis Viral Hepatitis-Related Cirrhosis (Hepatitis B, Hepatitis C) Autoimmune Cirrhosis Genetic and Metabolic Disorders-Related Cirrhosis) By Compensated vs. Decompensated Cirrhosis (Compensated Cirrhosis Decompensated Cirrhosis)-Growth, Future Prospects & Competitive Analysis, 2016 – 2030- https://www.credenceresearch.com/report/cirrhosis-market

Key Segments

By Etiology

Alcoholic Cirrhosis

Non-Alcoholic Fatty Liver Disease (NAFLD) Cirrhosis

Viral Hepatitis-Related Cirrhosis (Hepatitis B, Hepatitis C)

Autoimmune Cirrhosis

Genetic and Metabolic Disorders-Related Cirrhosis

By Compensated vs. Decompensated Cirrhosis

Compensated Cirrhosis

Decompensated Cirrhosis

Several factors contribute to the growth of the cirrhosis market worldwide:

Increasing Incidence and Prevalence: The global incidence and prevalence of cirrhosis have been steadily rising due to factors such as alcohol consumption, obesity, and viral hepatitis infections. As more people are diagnosed with cirrhosis, there is a growing need for effective treatments and management strategies.

Advancements in Medical Research: Ongoing research in the field of liver disease has led to a better understanding of cirrhosis and its underlying mechanisms. This research has paved the way for the development of innovative therapies and medications.

Rising Awareness: Increased awareness among both healthcare professionals and the general public about the risks of cirrhosis and the importance of early diagnosis and treatment has driven demand for cirrhosis-related healthcare services.

Government Initiatives: In many countries, governments and health organizations are taking steps to address the rising burden of liver diseases, including cirrhosis. This includes funding for research, public health campaigns, and initiatives to improve access to healthcare services.

Why to Buy This Report-

The report provides a qualitative as well as quantitative analysis of the global Cirrhosis Market by segments, current trends, drivers, restraints, opportunities, challenges, and market dynamics with the historical period from 2016-2020, the base year- 2021, and the projection period 2022-2028.

The report includes information on the competitive landscape, such as how the market's top competitors operate at the global, regional, and country levels.

Major nations in each region with their import/export statistics

The global Cirrhosis Market report also includes the analysis of the market at a global, regional, and country-level along with key market trends, major players analysis, market growth strategies, and key application areas.

Browse Complete Report- https://www.credenceresearch.com/report/cirrhosis-market

Visit our Website- https://www.credenceresearch.com/

Related Reports- https://www.credenceresearch.com/report/aloe-vera-based-skin-and-hair-products-market

Browse Our Blog- https://www.linkedin.com/pulse/cirrhosis-market-size-worth-usd-91571-million-globally-shukla

About Us -

Credence Research is a viable intelligence and market research platform that provides quantitative B2B research to more than 10,000 clients worldwide and is built on the Give principle. The company is a market research and consulting firm serving governments, non-legislative associations, non-profit organizations, and various organizations worldwide. We help our clients improve their execution in a lasting way and understand their most imperative objectives. For nearly a century, we’ve built a company well-prepared for this task.

Contact Us:

Office No 3 Second Floor, Abhilasha Bhawan, Pinto Park, Gwalior [M.P] 474005 India

[delvenservices]

Rapid Diagnostics Market Size, Share & Forecast: 2028

Rapid Diagnostics Market by Product (Glucose, Infectious Disease (Hepatitis C, Influenza), Coagulation), Platform (Microfluidics, Immunoassay), Mode of Purchase (Prescription, OTC), Enduser (Hospital, e-comm, Home Care), and Region (North America, Europe, Asia-Pacific, Middle East and Africa and South America)

Market Overview:

The Rapid Diagnostics market size is projected to reach a CAGR of 11.6% from 2022 to 2028.

Rapid Diagnostics are the medical techniques which are used for the diagnosis and the detection of the disease but are way to perform and are quick. These techniques play major role in the situation wherein the preliminary or the emergency situation similar to the ongoing pandemic. These test kits tend to provide the results in either 20 minutes or the same day.

The technological advancements in the sector along with the surge in the incidents of the infectious disease are some of the factors that have supported long-term expansion for Rapid Diagnostics Market.

COVID-19 had a positive effect on the market, as because the global demand has increased to various folds and also the shortage of lab-based testing facilities the demand for rapid diagnostics was increased.

Request Research Sample Pages: https://www.delvens.com/get-free-sample/rapid-diagnostics-market-trends-forecast-till-2028

Regional Analysis

North America is the most rapidly growing market and offers a huge opportunity for the industry, whose growth is driven by the incidents of lifestyle disorder becoming popular in the region and also the presence of the key players in the region.

Competitive Landscape

Key Players

Roche Diagnostics

Siemens Healthineers

Danaher Corporation

Becton Dickinson and Company

Abbott Laboratories

Quidel Diagnostics

Chembio Diagnostics

EKF Diagnostics

Trinity Biotech

Fluxergy

Recent Developments

In June 2019, FDA gave the approval to Roche diagnostics for VENTANA PD-L1 (SP142) Assay.

Make an Inquiry Before the Purchase: https://www.delvens.com/Inquire-before-buying/rapid-diagnostics-market-trends-forecast-till-2028

Reasons to Acquire

Increase your understanding of the market for identifying the best and suitable strategies and decisions on the basis of sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends and factors

Gain authentic and granular data access for Rapid Diagnostics Market so as to understand the trends and the factors involved behind changing market situations

Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future

In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns

Report Scope

Rapid Diagnostics Market is segmented into product, platform, mode of purchase, end users and region.

On the basis of Product

Glucose Monitoring Products

Cardiometabolic Monitoring Products

Infectious Disease Testing Products

Coagulation Monitoring Products

Pregnancy & Fertility Testing Products

Fecal Occult Testing Products

Hematology Testing Products

Tumor/Cancer Marker Testing Products

Urinalysis Testing Products

Drugs-of-abuse Testing Products

Cholesterol Testing Products

Other POC Products

On the basis of Purchase

OTC Testing Products

Prescription-based Testing Products

On the basis of End-Users

Outpatient & Ambulatory Care Facilities

Hospitals & Critical Care Centers

Home Care Settings 5

Other End Users

On the basis of Region

Asia Pacific

North America

Europe

South America

Middle East & Africa

Purchase the Research Report: https://www.delvens.com/checkout/rapid-diagnostics-market-trends-forecast-till-2028

About Us:

Delvens is a strategic advisory and consulting company headquartered in New Delhi, India. The company holds expertise in providing syndicated research reports, customized research reports and consulting services. Delvens qualitative and quantitative data is highly utilized by each level from niche to major markets, serving more than 1K prominent companies by assuring to provide the information on country, regional and global business environment. We have a database for more than 45 industries in more than 115+ major countries globally.

Delvens database assists the clients by providing in-depth information in crucial business decisions. Delvens offers significant facts and figures across various industries namely Healthcare, IT & Telecom, Chemicals & Materials, Semiconductor & Electronics, Energy, Pharmaceutical, Consumer Goods & Services, Food & Beverages. Our company provides an exhaustive and comprehensive understanding of the business environment.

Browse For More Related Reports:

Contact Us:

UNIT NO. 2126, TOWER B,

21ST FLOOR ALPHATHUM

SECTOR 90 NOIDA 201305, IN

+44-20-8638-5055

SALES@DELVENS.COM

[colinwilson11]

The Rising Super Generics Market Driven By Increased Accessibility Of Affordable Medicines

Super generics are generic pharmaceutical drugs that are therapeutically equivalent to brand-name drugs but are significantly cheaper than both branded and ordinary generics. Super generics help overcome price barriers for patients living with chronic diseases by offering high-quality medicines at a fraction of brand-name drug costs. They are developed through a complex process involving developing robust generic drug applications with focus on matching active ingredients and treatment efficacy of reference drugs. The Super Generics Market is driven by the need to enhance access to medicines for a broader patient base while controlling increasing healthcare costs.

Key Takeaways

The Super Generics Marketis estimated to be valued at US$ 84 Bn in 2024 and is expected to exhibit a CAGR of 8.3% over the forecast period 2024-2031.

Key players operating in the super generics market are Accord Healthcare, Alcon Laboratories, Azurity Pharmaceuticals, Baxter, and Dr. Reddy’s Laboratories. These companies are focusing on expanding their generics drug portfolios and enhancing manufacturing scale to tap the high-growth super generics market segment.

The rising prevalence of chronic diseases and increasing healthcare costs are driving robust demand for more affordable generic drugs. Super generics are being preferred over ordinary generics as they provide nearly equivalent efficacy at 60-70% lower costs than reference drugs.

Technological advancements are helping super generics players develop robust generic equivalents of complex drugs and molecules. This is expanding treatment access in disease areas that were previously addressed only through expensive brand medications. Continuous innovations will remain crucial for market leadership.

Market Trends

Increasing approvals for complex generics - Regulatory agencies are promoting faster approvals for generic versions of complex drugs treating conditions like cancer, hepatitis C, and multiple sclerosis. This will significantly boost the super generics market.

Focus on specialty drug segments - Major players are developing robust portfolios targeting specialty drug categories like oncology, CNS disorders, and autoimmune diseases that dominate the prescription landscape. This represents a massive opportunity.

Market Opportunities

Opening of emerging markets - Markets in Latin America, Middle East, Africa, and Asia still rely majorly on on-patent branded drugs due lack of alternatives. increased super generics access can transform healthcare in these regions.

Partnerships for difficult-to-copy drugs - Companies are tying up with specialized players for technologies and know-how to develop low-cost versions of biologics and other difficult drugs, presenting a long growth runway.

Impact Of COVID-19 On Super Generics Market Growth

The COVID-19 pandemic has adversely impacted the super generics market growth. During the peak of the pandemic in 2020-2021, many manufacturing facilities were shut down momentarily due to lockdowns imposed by various governments. This led to disrupted supply chains and shortage of APIs (Active Pharmaceutical Ingredients). Many generics drug formulations also faced shortage issues. The demand for life-saving generics drugs saw a sharp rise during the pandemic. However, the supply could not keep up with such heightened demand levels. This mismatch negatively impacted the market revenues during these periods.

As the pandemic situation gradually stabilizes with declining infection rates worldwide, the super generics market is expected to bounce back strongly. The overall demand for affordable generics drugs remains high. Many new products are also in the pipeline for launch post-COVID. With resumption of normal operations across manufacturing facilities, the supply chains are getting restored. The easy availability of generics drugs will be crucial for universal healthcare during the post-COVID era. The market is anticipated to demonstrate accelerated growth trajectory from 2022 onwards to makeup for the pandemic disruptions.

Geographical Regions With Highest Value Concentration In Super Generics Market

North America accounts for the largest share of the Super Generics Market in terms of value. The U.S. market contributes significantly to the high revenue generation from the region. Low drug prices and patent expirations in the U.S. provide lucrative opportunities for super generics companies. Europe is another leading regional market, driven by favorable pricing policies and high acceptance of generics drugs across major countries like Germany, France, U.K, Spain, and Italy.

Fastest Growing Regional Market For Super Generics

Asia Pacific region is poised to showcase the fastest growth in the Super Generics Market over the forecast period from 2024 to 2031. The expanding patient population, rising healthcare spending, and ongoing initiatives to enhance healthcare access are fueling the market demand in Asia Pacific economies such as India, China, Australia, Japan, and South Korea. Significant investments by international generics drug makers to tap opportunities in the growth markets of Asia Pacific will further support the region’s growth momentum.

Get more insights on this topic:  https://www.trendingwebwire.com/the-super-generics-market-set-for-growth-due-to-advancements-in-bioavailability-enhancement-technologies/

 

Author Bio:

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163 )

 

What Are The Key Data Covered In This Super Generics Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the Super Generics Market's growth between 2024 and 2031.

:- Accurate calculation of the size of the Super Generics Market and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- Super Generics Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of Super Generics Market vendors

FAQ’s

Q.1 What are the main factors influencing the Super Generics Market?

Q.2 Which companies are the major sources in this industry?

Q.3 What are the market’s opportunities, risks, and general structure?

Q.4 Which of the top Super Generics Market companies compare in terms of sales, revenue, and prices?

Q.5 Which businesses serve as the Super Generics Market’s distributors, traders, and dealers?

Q.6 How are market types and applications and deals, revenue, and value explored?

Q.7 What does a business area’s assessment of agreements, income, and value implicate?

*Note: 1. Source: Coherent Market Insights, Public sources, Desk research 2. We have leveraged AI tools to mine information and compile it

[factmrblog]

Forecasting the Future of the Beta Interferon Market (2023-2033)

The global beta interferon market was valued at approximately USD 10.38 billion in 2019 and is expected to grow at a CAGR of 7.0% from 2020 to 2033. Factors driving the growth of the market are the increase in the number of hospitalized patients and awareness about the role of beta interferon in treating chronic inflammatory and neurodegenerative diseases.

On the other hand, factors restraining the growth of the market include the high cost of drugs and side effects associated with them. Beta interferon has been used in the management of multiple sclerosis, Crohn’s Disease, and other autoimmune diseases. Moreover, rising research and development activities by major players are anticipated to create lucrative opportunities for market growth in the future.

Download Sample Copy of This Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=8395?VM

Key Companies Profiled

Xiamen Amoytop Biotech Co

Changchun Institute of Biological Products

Hainan Unipul Pharmaceutical

Kawin

Kexing Biopharm

Merck

Roche

Sinopharm

SP (Brinny) Company

Bristol-Myers Squibb

Competitive Landscape

Key players in the beta interferon market are focusing on producing advanced drugs to meet end users’ needs and earn more profits. Also, they are adopting organic and inorganic marketing tactics such as partnerships, mergers, and regional expansion by enhancing local supply, changing pricing trends, etc.

Fact.MR, a market research and competitive intelligence provider, reveals key marketing strategies of leading companies in the beta interferon market in its latest report.

Based on its most recent interactions with the United States Food and Drug Administration, in September 2022, Eiger BioPharmaceuticals, Inc. gave an update on the status of its intended request for an emergency-use approval of peginterferon lambda for the treatment of individuals with mild-to-moderate coronavirus.

Key Segments of Beta Interferon Industry Research

By Type :

Interferon Beta-1A

Interferon Beta-1B

Peginterferon Beta-1A

By Route of Administration :

Intramuscular

Subcutaneous

Intravenous

By Distribution Channel :

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Disease :

Multiple Sclerosis

Hepatitis C

Cancer

By Region :

North America

Latin America

Europe

Asia Pacific

MEA

Get Full Access of Complete Report: https://www.factmr.com/checkout/8395

Questionnaire answered in the Market outlook Report of Beta interferon market include:

What is the key strategy deployed by large players to maximize Beta interferon market growth?

What are the main challenges faced by players in the Beta interferon market Demand?

With the advent of technological advancement, how will the Beta interferon market landscape change over the forecast period?

What does player bring to the table which is unique as a strategy, and is easy to emulate for new investors in the Beta interferon market size?

Contact:

US Sales Office :11140 Rockville Pike Suite 400Rockville,

MD 20852United States

Tel: +1 (628) 251-1583

E-Mail: sales@factmr.com

[surajmarathedb1]

EUROPE POINT-OF-CARE DIAGNOSTICS Market Growth, Industry Size-Share, Global Trends, Key Players Strategies and Upcoming Demand

Data Bridge Market Research analyses that the EUROPE POINT-OF-CARE DIAGNOSTICS MARKET will project a compound annual growth rate (CAGR) of 10.22% during the forecast period of 2022-2029.

A world class EUROPE POINT-OF-CARE DIAGNOSTICS MARKET research report is formulated with the finest and advanced tools of collecting, recording, estimating and analysing market data. With the systematic and comprehensive market research study, this market research report offers the facts associated with any subject in the field of marketing for Healthcare industry. It gives superior ideas and solutions in terms of product trends, marketing strategy, future products, new geographical markets, future events, sales strategies, customer actions or behaviours. This EUROPE POINT-OF-CARE DIAGNOSTICS MARKET report has been prepared by considering several fragments of the present and upcoming market scenario.

EUROPE POINT-OF-CARE DIAGNOSTICS MARKET Scope and Market Size

The point-of-care diagnostics market is segmented on the basis of product, platform, prescription and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them in making strategic decisions for the identification of core market applications.

On the basis of product, the point-of-care diagnostics market is segmented into glucose monitoring products, cardio metabolic, infectious disease, coagulation, pregnancy and fertility, tumor or cancer marker, urinalysis, cholesterol, haematology, drugs-of-abuse, fecal occult and others. Glucose monitoring products is further sub segmented into strips, meters and lancets and lancing device. Cardiometabolic is further sub segmented into cardiac marker, blood gas or electrolytes and HBA1C. Infectious disease is further sub segmented into influenza, HIV, hepatitis C, sexually transmitted disease (STD), healthcare-associated infection (HAI), respiratory infection, tropical disease and other infectious disease. Coagulation is further sub segmented into PT or INR and activated clotting time (ACT or APTT). Pregnancy and fertility is further sub segmented into pregnancy test and fertility test.

On the basis of platform, the point-of-care diagnostics market is segmented into lateral flow assays (immunochromatography tests), dipsticks, microfluidics, molecular diagnostics and immunoassays.

On the basis of prescription, the point-of-care diagnostics market is segmented into prescription-based testing and OTC testing.

On the basis of end user, the point-of-care diagnostics market is segmented into clinical laboratories, outpatient healthcare and ambulatory care settings, hospitals or critical care centers, home care, research laboratories and other.

Get the Free sample copy of the report here:

Some of the key questions answered in this report:

How has the EUROPE POINT-OF-CARE DIAGNOSTICS MARKET performed so far and how will it perform in the coming years?

What has been the impact of COVID-19 on the EUROPE POINT-OF-CARE DIAGNOSTICS MARKET?

What are the key regional markets?

What are the key driving factors and challenges in the industry?

What is the structure of the EUROPE POINT-OF-CARE DIAGNOSTICS MARKET and who are the key players?

Market Analysis and Insights:  EUROPE POINT-OF-CARE DIAGNOSTICS MARKET

The point-of-care diagnostics market is expected to witness market growth at a rate of 10.22% in the forecast period of 2022 to 2029. Data Bridge Market Research report on point-of-care diagnostics market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecast period while providing their impacts on the market’s growth. The rise in the incidence of target diseases is escalating the growth of point-of-care diagnostics market.

Point-Of-Care diagnostics are the approaches that are utilized to identify infections early and quickly. Such procedures are extremely sensitive, cost-efficient and produce results within a short timeframe. These testing methods are utilized by schools, physicians, outpatients, clinical labs and home health.

Major factors that are expected to boost the growth of the point-of-care diagnostics market in the forecast period are the rise in the need for home healthcare has pushed the manufacturers. Furthermore, the growing importance of point-of-care diagnostics in the environmental monitoring and public health is further anticipated to propel the growth of the point-of-care diagnostics market. Moreover, the technological developments and new product releases is further estimated to cushion the growth of the point-of-care diagnostics market. On the other hand, the expenses pressure because of repayment cuts and budget restriction is further projected to impede the growth of the point-of-care diagnostics market in the timeline period.

EUROPE POINT-OF-CARE DIAGNOSTICS MARKET - Regional Level Analysis

The countries covered in the point-of-care diagnostics market report are the Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe.

EUROPE POINT-OF-CARE DIAGNOSTICS MARKET - Share Analysis: 

The North America point-of-care diagnostics market competitive landscape provides details by a competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to the point-of-care diagnostics market.

Key player - EUROPE POINT-OF-CARE DIAGNOSTICS MARKET 

Some of the major players operating in the EUROPE POINT-OF-CARE DIAGNOSTICS MARKET are Abbott, Danaher, BD, F. Hoffmann-La Roche Ltd, Johnson & Johnson Services, Inc., Instrumentation Laboratory S.p.A. – Werfen, bioMérieux SA, Trividia Health, Inc., QIAGEN, Sekisui Diagnostics, Siemens Healthcare GmbH, Quidel Corporation, Spectral Medical Inc., Abaxis, Nova Biomedical, Trinity Biotech, Alfa Scientific Designs, Inc., ?PTS Diagnostics, Bio-Rad Laboratories, Inc., and Medica Corporation among others.

Get Full Access of Report@

https://www.databridgemarketresearch.com/reports/europe-point-of-care-diagnostics-market

MAJOR TOC OF THE REPORT

Chapter One: Introduction

Chapter Two: Scope and Market Size

Chapter Three: Analysis and Insights

Chapter Four: Country Level Analysis

Chapter Five: Share Analysis

Chapter Six: Key player

Get TOC Details:

https://www.databridgemarketresearch.com/toc/?dbmr=europe-point-of-care-diagnostics-market Top Trending Reports:

Global Autoclave Market

Global Proctoscope Market

Global Molecular Methods Market

Global Wound Debridement Market

Global Human Papilloma Virus Testing Market

Global Non-Small Cell Lung Cancer Market

Global CPAP Market

Global RNA Markers Market

Global Healthcare Cloud Computing Market

Global Medical Image Management Market

Global Pharmacogenetic Testing Market

Global Hemodialysis Services Market

Global Hemostatic Wound Dressing Market

Global Interventional Radiology Products Market

Global Lab Accessories Market

Global Label-free Array Systems Market

Global Laboratory Gas Generators Market

Global Life Science Analytics Market

Global Mediastinoscopes Market

Global Medical Alert System Market

Global EDS, WDS, EBSD, Micro-XRF Instruments Market

Global Direct-to-Consumer (DTC) Genetic Testing Market

Global Q- Polymerase Chain Reaction and D- Polymerase Chain Reaction Devices Market

Asia-Pacific (APAC) Q-PCR and D-PCR Devices Market

Europe Q-PCR and D-PCR Devices Market

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

Contact:

Data Bridge Market Research

Tel: +1-888-386.8-2818

Email: Sopan.gedam@databridgemarketresearch.com

[impossibledeanmakerwombat]

Anti-Viral Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends And Forecast 2023 to 2032

The global anti-viral drugs market is expected to be valued at US$ 59,596.8 Million in 2022. The induction of the generic version of antiviral medicines and rising awareness about the availability of various vaccines for viral infections is affecting the growth throughout the forecast period. The overall demand for Anti-Viral Drugs is projected to grow at a CAGR of 3.9% between 2022 and 2032, totaling around US$ 87,675.36 Million by 2032.

Anti-viral drugs are medicines which are used specially for treating viral infections. Most anti-viral drugs are used for particular viral infections, similar to antibiotics, while a broad-spectrum anti-viral drug is effective against a varied range of viruses. Antiviral drugs do not kill their target pathogen, instead they inhibit the development of those viruses.

The global anti-viral drugs market is projected to register a moderate growth rate in the pharmaceutical market and which is anticipated to increase due to rise in awareness level, increase in the diseased population and introduction of new drugs with improved efficacy.

Some major patents are reaching their expiry during forecast period, such as for Combivir, Sustiva, Tenofovir, Tamiflu, Relenza and Telbivudine. The patent expiries of these blockbuster drugs is expected to trigger generic competition in the antivirals therapeutics market, which will make the market more competitive.

The late stage pipeline drugs are expected to enter the market, which will positively impact the market. Most antivirals are considered comparatively harmless to host, and therefore are used to treat infections. They are different from viricides, which are not used for medication but can destroy or deactivate virus particles, either outside or inside the body.

The anti-viral drugs are used in the treatment of patients suffering from herpes viruses, HIV, influenza A and B viruses and the hepatitis B and C viruses.

Request Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1951

Anti-viral Drugs Market: Drivers and Restraints

As of October 2013, according to WHO, there were around 35.3 Mn people globally, infected with HIV. Therefore, increased viral infection incidences is one of the important factors that drives the anti-viral drugs market growth. Because of the solid R&D activities, newer and advanced treatments and formulations, such as vaccines, combination therapy and others, are being introduced in the market.

Hence, strong R&D is one of the crucial factors in the anti-viral drugs market growth. On the other hand, high risk of failure, high cost of R&D and therapy, and government austerity are some of threats expected to hinder the growth of market.

These are some factors anticipated to fuel growth of global anti-viral drugs market within the forecast period of 2016-2026. However, increasing usage of natural products and high cost of developing drugs are the key challenges faced by the market.

Anti-viral Drugs Market: Overview

The generic market of anti-viral drugs is presently dominated by products such as didanosine, zidovudine, lamivudine and stavudine. The biggest driver of overall anti-viral drugs market is Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) therapeutic sales which accounted for more than half the share of the market 2010.

At the end of 2012, 9.7 million people in low-income and middle-income countries were on antiretroviral treatment (ART). According to WHO, in 2012, number of patients on ART increased by 1.6 Mn, the largest increase in one year.

Nearly four out of five people were freshly put on treatment in the sub-Saharan Africa. In 21 African countries with a high burden of HIV, two out of three people in need are receiving treatment, and two out of three positive pregnant women are receiving antiretroviral drugs to prevent HIV transmission to their infants.

Ask For Customization @ https://www.futuremarketinsights.com/customization-available/rep-gb-1951

Anti-viral Drugs Market: Regional Overview

Region wise, the global anti-viral drugs market is classified into regions namely, North America, Eastern Europe, Western Europe, Latin America, Japan, Asia-Pacific, Middle East and Africa. According to WHO, in countries with Major ART scale-up such as Brazil or China, the death rate among people living with HIV has decreased by 80%. In 2015, in India the number of people living with HIV were 2.1 Mn and in U.S. the number was around 1.2 Mn in the year 2013.

Anti-viral Drugs Market: Key Players

Some of the key players in global anti-viral drugs market, which are focusing on general molecular mechanisms of antiviral drugs rather than therapies for individual viruses, include Roche, Gilead, GlaxoSmithKline, Bristol-Myers-Squibb, Abbott, AstraZeneca, Cipla, Schering-Plough, Johnson & Johnson, Merck & Co and others.

Key Segments Covered in the Anti-Viral Drugs Industry Analysis

Anti-Viral Drugs Market by Product type:

Hepatitis-C antivirals

HIV antivirals

Herpes antivirals

Hepatitis-B antivirals

Influenza antivirals

Others (Pneumonia, Flu, etc.)

Anti-Viral Drugs Market by End-user:

Hospitals

Clinics

Ambulatory Surgical Centers

Anti-Viral Drugs Market by Region:

North America Anti-Viral Drugs Market

Latin America Anti-Viral Drugs Market

Europe Anti-Viral Drugs Market

Asia Pacific Anti-Viral Drugs Market

The Middle East & Africa Anti-Viral Drugs Market

Ask An Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-1951

[ankit2396]

Hepatitis C Drug Market Size, Growth, Revenue, Opportunities And Geographical Forecast Till 2030

Global Hepatitis C Drug Market Size research report 2023 offers in-depth assessment of revenue growth, market definition, segmentation, industry potential, influential trends for understanding the future outlook and current prospects for the market.

Get a Sample Copy of the Report at – https://www.fortunebusinessinsights.com/industry-reports/hepatitis-c-drug-market-101562